Reports Q2 revenue $5.5M, consensus $8.32M. “Thus far, 2025 has been a year of breakthrough accomplishments for Protagonist, as we saw rusfertide the topic of the prestigious ASCO Plenary Session in May, the announcement of an oral and injectable triple agonist anti-obesity peptide development candidate in June, and most recently the first ever NDA filing of icotrokinra for psoriasis last month,” said Dinesh V. Patel, Ph.D., the Company’s President and CEO. “Over the coming months, we look forward to the NDA filing of rusfertide for polycythemia vera, and advancing our wholly owned early-stage assets PN-881 and PN-477 into clinical and IND-enabling studies respectively.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics’ Rusfertide Study: Long-term Safety in Focus
- Optimistic Buy Rating for Protagonist Therapeutics Driven by Promising NDA Submission and Market Potential of Icotrokinra
- Protagonist Therapeutics Positioned for Growth with Icotrokinra’s Strong FDA Approval Prospects and Strategic Partnerships
- Protagonist Therapeutics, Johnson & Johnson submit icotrokinra NDA to FDA
- Protagonist announces NDA submission by Johnson & Johnson for icotrokinra